202 related articles for article (PubMed ID: 17051950)
1. Dose escalation with three-dimensional conformal radiotherapy for prostate cancer. Is more dose really better in high-risk patients treated with androgen deprivation?
Zapatero A; Ríos P; Marín A; Mínguez R; García-Vicente F
Clin Oncol (R Coll Radiol); 2006 Oct; 18(8):600-7. PubMed ID: 17051950
[TBL] [Abstract][Full Text] [Related]
2. Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: Does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study.
Zapatero A; Valcárcel F; Calvo FA; Algás R; Béjar A; Maldonado J; Villá S
J Clin Oncol; 2005 Sep; 23(27):6561-8. PubMed ID: 16170164
[TBL] [Abstract][Full Text] [Related]
3. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial.
Zapatero A; Guerrero A; Maldonado X; Alvarez A; Gonzalez San Segundo C; Cabeza Rodríguez MA; Macias V; Pedro Olive A; Casas F; Boladeras A; de Vidales CM; Vazquez de la Torre ML; Villà S; Perez de la Haza A; Calvo FA
Lancet Oncol; 2015 Mar; 16(3):320-7. PubMed ID: 25702876
[TBL] [Abstract][Full Text] [Related]
4. Long-term results after high-dose radiotherapy and adjuvant hormones in prostate cancer: how curable is high-risk disease?
Zapatero A; García-Vicente F; Martín de Vidales C; Cruz Conde A; Ibáñez Y; Fernández I; Rabadán M
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1279-85. PubMed ID: 20932659
[TBL] [Abstract][Full Text] [Related]
5. [Dose escalation with three dimensional conformal radiotherapy for prostate cancer: more is better?].
Zapatero A; Marín A; Cruz-Conde A; López MA; Mínguez R; García-Vicente F
Actas Urol Esp; 2005 Oct; 29(9):834-41. PubMed ID: 16353769
[TBL] [Abstract][Full Text] [Related]
6. Is androgen deprivation therapy necessary in all intermediate-risk prostate cancer patients treated in the dose escalation era?
Castle KO; Hoffman KE; Levy LB; Lee AK; Choi S; Nguyen QN; Frank SJ; Pugh TJ; McGuire SE; Kuban DA
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):693-9. PubMed ID: 22836052
[TBL] [Abstract][Full Text] [Related]
7. Stage T3 prostate cancer: a nonrandomized comparison between definitive irradiation and induction hormonal manipulation plus prostatectomy.
Corn BW; Valicenti RK; Mulholland SG; Hyslop T; Gomella L
Urology; 1998 May; 51(5):782-7. PubMed ID: 9610592
[TBL] [Abstract][Full Text] [Related]
8. High-dose radiation employing external beam radiotherapy and high-dose rate brachytherapy with and without neoadjuvant androgen deprivation for prostate cancer patients with intermediate- and high-risk features.
Vargas C; Martínez A; Galalae R; Demanes J; Harsolia A; Schour L; Nuernberg N; Gonzalez J
Prostate Cancer Prostatic Dis; 2006; 9(3):245-53. PubMed ID: 16786040
[TBL] [Abstract][Full Text] [Related]
9. Improved survival for patients with prostate cancer receiving high-dose-rate brachytherapy boost to EBRT compared with EBRT alone.
Kent AR; Matheson B; Millar JL
Brachytherapy; 2019; 18(3):313-321. PubMed ID: 30846330
[TBL] [Abstract][Full Text] [Related]
10. High-dose radiotherapy plus prolonged hormone therapy in CT2-3 prostatic carcinoma: is it useful?
Cellini N; Pompei L; Fortuna G; Ammaturo MV; De Paula U; Luzi S; Mattiucci GC; Morganti AG; Digesù C; Rosetto ME; Palloni T; Petrongari MG; Gentile P; Deodato F; Valentini V
Tumori; 2004; 90(2):201-7. PubMed ID: 15237583
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant androgen deprivation and prostate gland shrinkage during conformal radiotherapy.
Sanguineti G; Marcenaro M; Franzone P; Foppiano F; Vitale V
Radiother Oncol; 2003 Feb; 66(2):151-7. PubMed ID: 12648786
[TBL] [Abstract][Full Text] [Related]
12. Dose escalation for prostate cancer radiotherapy: predictors of long-term biochemical tumor control and distant metastases-free survival outcomes.
Zelefsky MJ; Pei X; Chou JF; Schechter M; Kollmeier M; Cox B; Yamada Y; Fidaleo A; Sperling D; Happersett L; Zhang Z
Eur Urol; 2011 Dec; 60(6):1133-9. PubMed ID: 21889832
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant androgen deprivation impacts late rectal toxicity after conformal radiotherapy of prostate carcinoma.
Sanguineti G; Agostinelli S; Foppiano F; Franzone P; Garelli S; Marcenaro M; Orsatti M; Vitale V
Br J Cancer; 2002 Jun; 86(12):1843-7. PubMed ID: 12085173
[TBL] [Abstract][Full Text] [Related]
14. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
[TBL] [Abstract][Full Text] [Related]
15. Biochemical response after 3-d conformal radiotherapy of localized prostate cancer to a total dose of 66 gy 4-year results.
Wachter-Gerstner N; Wachter S; Goldner G; Nechvile E; Pötter R
Strahlenther Onkol; 2002 Oct; 178(10):542-7. PubMed ID: 12386785
[TBL] [Abstract][Full Text] [Related]
16. Is hormone therapy a protective factor for late hematuria after high-dose radiotherapy in prostate cancer?
Zapatero A; García-Vicente F; Sevillano D; Martín de Vidales C; Ferrer C; Torres JJ; Minguez R; Rabadán M
Urology; 2008 Nov; 72(5):1130-4. PubMed ID: 18400265
[TBL] [Abstract][Full Text] [Related]
17. Improvement in relapse-free survival throughout the PSA era in patients with localized prostate cancer treated with definitive radiotherapy: year of treatment an independent predictor of outcome.
Kupelian PA; Buchsbaum JC; Elshaikh MA; Reddy CA; Klein EA
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):629-34. PubMed ID: 14529766
[TBL] [Abstract][Full Text] [Related]
18. [Biochemical control after conformal, 3 dimensional radiotherapy of prostatic carcinoma].
Geinitz H; Zimmermann F; von Wedel E; Thamm R; Busch R; Feldmann HJ; Molls M
Strahlenther Onkol; 2002 Jul; 178(7):369-77. PubMed ID: 12163991
[TBL] [Abstract][Full Text] [Related]
19. Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial.
Dearnaley DP; Jovic G; Syndikus I; Khoo V; Cowan RA; Graham JD; Aird EG; Bottomley D; Huddart RA; Jose CC; Matthews JH; Millar JL; Murphy C; Russell JM; Scrase CD; Parmar MK; Sydes MR
Lancet Oncol; 2014 Apr; 15(4):464-73. PubMed ID: 24581940
[TBL] [Abstract][Full Text] [Related]
20. Impact of biochemical failure on overall survival after radiation therapy for localized prostate cancer in the PSA era.
Kupelian PA; Buchsbaum JC; Patel C; Elshaikh M; Reddy CA; Zippe C; Klein EA
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):704-11. PubMed ID: 11849793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]